Myosin Therapeutics Named to NCI's 2026-2027 Investor Showcase
Jupiter, Florida – September 19, 2026 -- Myosin Therapeutics, Inc. has been selected as one of just 30 companies for the National Cancer Institute's 2026–2027 Investor Initiatives Showcase, a distinction drawn from NCI's full portfolio of funded companies following a competitive review by more than 70 third-party investors and strategic partners.
NCI selects Myosin from a competitive field of oncology innovators
The 2026–2027 cohort spans biopharmaceuticals, medical devices, diagnostics and digital health, covering first-in-class therapeutics, cell and immune therapies, radioligand therapies, antibody-drug conjugates, RNA medicines, precision drug delivery, AI-enabled cancer technologies, liquid biopsy and multi-omics platforms. Myosin enters this group with a mechanics-based approach that targets molecular nanomotors underlying cancer cell growth, invasion and survival.